<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas13513-bib-0007">
 <label>7</label>
 <mixed-citation publication-type="journal" id="cas13513-cit-0007">
  <string-name>
   <surname>Coiffer</surname>
   <given-names>B</given-names>
  </string-name>, 
  <string-name>
   <surname>Pro</surname>
   <given-names>B</given-names>
  </string-name>, 
  <string-name>
   <surname>Prince</surname>
   <given-names>HM</given-names>
  </string-name>, et al. 
  <article-title>Results from a pivotal, open‐label, phase II study of romidepsin in relapsed or refractory peripheral T‐cell lymphoma after prior systemic therapy</article-title>. 
  <source>J Clin Oncol</source>. 
  <year>2012</year>;
  <volume>30</volume>:
  <fpage>631</fpage>‐
  <lpage>636</lpage>.
  <pub-id pub-id-type="pmid">22271479</pub-id>
 </mixed-citation>
</ref>
